
Exclusive: Geely, Renault in talks over sales, manufacturing deals in Brazil, sources say
PARIS/SHANGHAI, Feb 12 (Reuters) - French automaker Renault (RENA.PA), opens new tab and its Chinese partner Geely (0175.HK), opens new tab (GEELY.UL) plan to announce a deal later this month on expanding their cooperation to Brazil, three sources said, as they seek new growth markets amid broadening global trade wars.
The two firms created a thermal engine joint venture last year and have since also started selling cars produced in a jointly owned factory in South Korea.
They are now planning to further expand their partnership to Brazil, and are working on a preliminary deal that they aim to announce later this month, the sources familiar with the matter said. They declined to be named as the talks are not public yet.
Under the deal, the Chinese firm would start using Renault's Brazilian retail network as early as this year to begin sales of Geely-branded vehicles exported from China, two of the sources said.
The deal would also see Geely taking a minority stake in Renault Brazil and using the latter's Curitiba plant to assemble vehicles there, the two sources said. It was not immediately clear how big the potential investment would be.
Renault and Geely declined to comment. The plan for Geely to build its presence in Brazil by selling exported cars via Renault's retail network has not previously been reported. Les Echos had earlier outlined their talks on investment and local production.
The move will help boost capacity usage at Renault's plant in Brazil, the French firm's fifth largest overseas market, and aligns with its broader plan to reduce its reliance on the European market.
It would also help Geely, whose main export market is Europe, expand into new markets as it grapples with bruising price competition at home and hefty tariffs imposed by several developed markets including the U.S., Canada and the EU on China-made vehicles.
Amid rising trade tensions and overcapacity in China, Chinese automakers have been exploring opportunities in markets such as Russia, South America, the Middle East and Africa for export growth.
Brazil was the fastest-growing market for exports of EVs and plug-in hybrids from China last year, with shipments more than doubling to 152,000 units, according to Cui Dongshu, secretary general of the China Passenger Car Association.
It also became the second largest market for Chinese new energy vehicles - which include electric and hybrid models - after Belgium, he said.
In Brazil, Geely would sell cars under its own brand, unlike in the Korean partnership which currently focuses on a single Renault-branded model, the Grand Koleos, built on Geely's platform and manufactured in a Renault-controlled plant in Busan, South Korea.
Technical details of the partnership in Brazil are still being considered, and one of the sources said that Geely could set up its multi-energy platform in the Renault plant to manufacture gasoline cars, hybrid cars and pure EVs.
Stay up to date with the latest news, trends and innovations that are driving the global automotive industry with the Reuters Auto File newsletter. Sign up here.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Reuters
17 minutes ago
- Reuters
Metsera rises as experimental weight-loss drug shows promise in small early-stage trial
June 9 (Reuters) - Shares of weight-loss drug developer Metsera (MTSR.O), opens new tab gained as much as 25% on Monday after the company's experimental drug helped patients lose weight in a small, early-stage trial, showing potential for a monthly dosing regime. The drug developer, which went public in January, is one of the many that are eyeing the lucrative market of weight-loss drugs that have been dominated by GLP-1 drugs from Novo Nordisk ( opens new tab and Eli Lilly (LLY.N), opens new tab. The drug, MET-233i, helped patients lose 8.4% of their weight, when adjusted for placebo, at 36 weeks. The drug belongs to a class of medicines which mimic the pancreatic hormone amylin that is co-secreted with insulin. It is being developed as a standalone treatment, and in combination with the company's other GLP-1 drug MET-097i. The two hormones combined suppress hunger, help control patients' blood glucose. Metsera's shares, which touched $35.19 in early trading, were up 5% at midday. The first wave of obesity drugs was based mainly on the gut hormone GLP-1, but drugmakers are looking for medicines that target other hormones or help preserve muscle while losing fat for their next generation of drugs. Data from Novo Nordisk's experimental drug CagriSema, which was touted to be the successor of its blockbuster obesity drug Wegovy, has so far fallen below investor expectations. Data from Metsera's 80-patient study showed that its drug has a half life of about 19 days, supporting once-a-month dosing. This compares to the five to seven days for Lilly's Zepbound and Novo's Wegovy that are taken weekly, said Evercore ISI analyst Umer Raffat. The so-called half life of a drug refers to the time it takes for the initial dose of the medicine to decrease by half in a patient's body. It helps determine how frequently a drug should be taken to achieve benefits. Drugmaker AstraZeneca (AZN.L), opens new tab is also testing an amylin-based obesity drug in early trials.


Reuters
2 hours ago
- Reuters
US wholesale inventories in April revised higher
WASHINGTON, June 9 (Reuters) - U.S. wholesale inventories increased in April amid stockpiling of prescription medication in anticipation of tariffs from the Trump administration. Stocks at wholesalers rose 0.2% instead of being unchanged, as estimated last month, the Commerce Department's Census Bureau said on Monday. Economists polled by Reuters had expected last month's estimate would be unrevised. Inventories, a key part of gross domestic product, climbed 0.3% in March. They advanced 2.3% on a year-over-year basis in April. Wholesale stocks of prescription medication surged 1.3% in April. There were also increases in apparel, motor vehicle, groceries and professional equipment inventories. President Donald Trump has said he would impose tariffs on imports of pharmaceutical products that have long been spared from past trade disputes due to the potential for harm to patients. Apart from drugmakers, businesses front-loaded imports in the first quarter, seeking to avoid Trump's sweeping duties on foreign goods, resulting in a large trade deficit that subtracted a record 4.90 percentage points from GDP. The front-running faded in April, leading to a record decline in imports and the overall trade deficit. While the contraction in the deficit at face value suggests trade could significantly add to gross domestic product in the second quarter, economists say some of the boost could be offset by low inventories. Inventory accumulation increased at a rate of $163.0 billion in the first quarter. The economy contracted at a 0.2% annualized rate in the January-March period, the first GDP decline in three years. It grew at a 2.4% pace in the fourth quarter. Sales at wholesalers edged up 0.1% in April after jumping 0.8% in March. At April's sales pace it would take wholesalers 1.30 months to clear shelves, unchanged from March.


Daily Mirror
2 hours ago
- Daily Mirror
Man Utd's next three transfers after Mbeumo signing as four players set to leave
Manchester United have already splashed the cash in the summer transfer window and are aiming to make Bryan Mbeumo their third signing of the window but are still aiming for more Manchester United still want to make THREE more signings once they get a move for Bryan Mbeumo complete. The Red Devils have made the Brentford forward one of their priority targets for the coming weeks. United have already approached the Bees for a deal but as yet, there is no agreement for the forward to move to Old Trafford. There may be one slight issue given Tottenham have forced themselves into contention, with Brentford boss Thomas Frank closing in on a switch to North London. But United are still pressing ahead with a move. And once Mbeumo completes a switch, the club will then move onto their other targets. United are interested in signing a new goalkeeper. Andre Onana has struggled to convince since his arrival from Inter Milan, and Gianuigi Donnarumma has emerged as a contender for a move - according to French reports - with just a year remaining on his contract with current side Paris Saint-Germain. Speaking recently about his future, he said: 'New deal or leaving? We will see what happens… I don't know. It's time to enjoy this magic season now. I will go on holiday and then we will see.' That situation may well not revolve itself until next summer, particularly given United's finances at present means they're unlikely to be able to pay anything like what PSG would want to part ways with the Italian 12 months early. But regardless, a new man between the sticks is likely to still arrive as the club have interest in bringing in a new No.2 as well. At the other end of the pitch, United are also keen to sign a new striker after their goalscoring woes last term. Viktor Gyokeres is a long-term target, while Victor Osimhen could also be an option after rejecting a move to Saudi Arabia. However, there is a slight issue when it comes to a new forward, with Rasmus Hojlund claiming that he is hoping to stay at the club beyond this summer. He said: 'I have a contract until 2030, so I expect to play for Manchester United. I'm looking forward to going on a summer vacation, and then I'm fully dedicated to the project that's underway. "I know I can't get much out of reading things. I know what the facts are, and that is that I have a contract with Manchester United until 2030. I expect to play there, so I'm just getting ready for some summer vacation and then hopefully a good pre-season." Who do you think Man United should sign? Share your thoughts in the comments below Finally, a new midfielder is also on United's shopping list for the remainder of the window. Atalanta star Ederson has been linked in the past and if it's not him then a similar all-action type should arrive. The Red Devils are determined to bid farewell to a few players to bolster their funds. Marcus Rashford, Antony and Jadon Sancho are all expected to leave the club following loan spells away from Old Trafford, with the trio all available for sale if the price is right. United's issue is all three have good contracts that they won't just want to give up. Almost certainly out the door is Alejandro Garnacho, who has been linked with Napoli, and has been told he has no future at the club under Amorim. Join our new MAN UTD WhatsApp community and receive your daily dose of Manchester United content from Mirror Football. We also treat our community members to special offers, promotions, and adverts from us and our partners. If you don't like our community, you can check out any time you like. If you're curious, you can read our Privacy Notice.